BJDX Bluejay Diagnostics Inc
Company Analysis
Latest News
Bluejay Diagnostics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 06, 2026
Bluejay Diagnostics is expected to report zero revenue for the third quarter of 2026 as its core Symphony platform remains pre-commercial, with consensus EPS...
Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split Effective November 3, 2026
Bluejay Diagnostics, Inc. (BJDX) has implemented a 1-for-4 reverse stock split of its common stock, which became effective on November 3, 2026. This action,...
Bluejay Diagnostics Achieves Key Manufacturing Milestone for Symphony™ Platform
Bluejay Diagnostics, Inc. announced it has met a critical contractual milestone by establishing a manufacturing site for its Symphony™ diagnostic cartridges....
Bluejay Diagnostics Announces Baseline Clinical Data from SYMON-II Sepsis Study
Bluejay Diagnostics announced baseline clinical characteristics from its SYMON-II clinical validation study for the Symphony™ IL-6 Test, which is being...
Bluejay Diagnostics Signs Distribution Agreement to Access U.S. Federal Healthcare Markets
Bluejay Diagnostics, Inc. has entered into a strategic distribution, co-marketing, and partnership agreement with Lovell Government Services, Inc., a firm...
Bluejay Diagnostics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Analysts expect Bluejay Diagnostics to report zero revenue for Q2 2026 as the company remains in a pre-commercial development phase, with EPS projected at a...
Bluejay Diagnostics Completes Patient Enrollment for Pivotal SYMON-II Sepsis Trial
Bluejay Diagnostics (NASDAQ: BJDX) announced it has successfully completed patient enrollment for its SYMON-II multicenter clinical validation study. The...